The future of protein biomarker research in type 2 diabetes mellitus
INTRODUCTION: The onset of type 2 diabetes mellitus (T2DM) is strongly associated with obesity and subsequent perturbations in immuno-metabolic responses. To understand the complexity of these systemic changes and better monitor the health status of people at risk, validated clinical biomarkers are needed. Omics technologies are increasingly applied to measure the interplay of genes, proteins and metabolites in biological systems, which is imperative in understanding molecular mechanisms of disease and selecting the best possible molecular biomarkers for clinical use. Areas covered: This review describes the complex onset of T2DM, the contribution of obesity and adipose tissue inflammation to the T2DM disease mechanism, and the output of current biomarker strategies. A new biomarker approach is described that combines published and new self-generated data to merge multiple -omes (i.e. genome, proteome, metabolome etc.) toward understanding of mechanism of disease on the individual level and design multiparameter biomarker panels that drive significant impacts on personalized healthcare. Expert commentary: We here propose an approach to use cross-omics analyses to contextualize published biomarker data and better understand molecular mechanisms of health and disease. This will improve the current and future innovation gaps in translation of discovered putative biomarkers to clinically applicable biomarker tests.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Expert review of proteomics - 16(2019), 2 vom: 11. Feb., Seite 105-115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tans, Roel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker innovation gaps |
|---|
| Anmerkungen: |
Date Completed 12.08.2019 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14789450.2018.1551134 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290998034 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290998034 | ||
| 003 | DE-627 | ||
| 005 | 20231225065929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14789450.2018.1551134 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0969.xml |
| 035 | |a (DE-627)NLM290998034 | ||
| 035 | |a (NLM)30468403 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tans, Roel |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The future of protein biomarker research in type 2 diabetes mellitus |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2019 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The onset of type 2 diabetes mellitus (T2DM) is strongly associated with obesity and subsequent perturbations in immuno-metabolic responses. To understand the complexity of these systemic changes and better monitor the health status of people at risk, validated clinical biomarkers are needed. Omics technologies are increasingly applied to measure the interplay of genes, proteins and metabolites in biological systems, which is imperative in understanding molecular mechanisms of disease and selecting the best possible molecular biomarkers for clinical use. Areas covered: This review describes the complex onset of T2DM, the contribution of obesity and adipose tissue inflammation to the T2DM disease mechanism, and the output of current biomarker strategies. A new biomarker approach is described that combines published and new self-generated data to merge multiple -omes (i.e. genome, proteome, metabolome etc.) toward understanding of mechanism of disease on the individual level and design multiparameter biomarker panels that drive significant impacts on personalized healthcare. Expert commentary: We here propose an approach to use cross-omics analyses to contextualize published biomarker data and better understand molecular mechanisms of health and disease. This will improve the current and future innovation gaps in translation of discovered putative biomarkers to clinically applicable biomarker tests | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biomarker innovation gaps | |
| 650 | 4 | |a translational medicine | |
| 650 | 4 | |a type 2 diabetes mellitus | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Verschuren, Lars |e verfasserin |4 aut | |
| 700 | 1 | |a Wessels, Hans J C T |e verfasserin |4 aut | |
| 700 | 1 | |a Bakker, Stephan J L |e verfasserin |4 aut | |
| 700 | 1 | |a Tack, Cees J |e verfasserin |4 aut | |
| 700 | 1 | |a Gloerich, Jolein |e verfasserin |4 aut | |
| 700 | 1 | |a van Gool, Alain J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of proteomics |d 2004 |g 16(2019), 2 vom: 11. Feb., Seite 105-115 |w (DE-627)NLM155364049 |x 1744-8387 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2019 |g number:2 |g day:11 |g month:02 |g pages:105-115 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14789450.2018.1551134 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2019 |e 2 |b 11 |c 02 |h 105-115 | ||